ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

RNAZ TransCode Therapeutics Inc

0.5839
-0.0031 (-0.53%)
Last Updated: 11:48:08
Delayed by 15 minutes

Period:

Draw Mode:

Volume 261,263
Bid Price 0.5839
Ask Price 0.584
News -
Day High 0.606

Low
0.42

52 Week Range

High
309.60

Day Low 0.56
Share Name Share Symbol Market Stock Type
TransCode Therapeutics Inc RNAZ NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0031 -0.53% 0.5839 11:48:08
Open Price Low Price High Price Close Price Previous Close
0.606 0.56 0.606 0.587
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
587 261,263 US$ 0.5864905 US$ 153,228 - 0.42 - 309.60
Last Trade Type Quantity Price Currency
11:52:35 1 US$ 0.584 USD

TransCode Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
363.92k 627.44k - 0 -18.55M -29.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

TransCode Therapeutics News

Date Time Source News Article
4/15/202408:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate..
4/03/202408:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides..
3/28/202407:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel..
3/11/202408:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress..
3/06/202415:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe..
2/20/202407:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States..
2/15/202415:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202419:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
1/31/202415:33Edgar (US Regulatory)Form 8-K - Current report
1/31/202415:05GlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with..
1/29/202407:30GlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration..
1/22/202415:45Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RNAZ Message Board. Create One! See More Posts on RNAZ Message Board See More Message Board Posts

Historical RNAZ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.4590.6290.420.5478568666,0060.124927.21%
1 Month0.67120.6960.420.546111473,589-0.0873-13.01%
3 Months0.56210.760.420.6249813405,2000.02183.88%
6 Months12.8019.4240.427.631,625,536-12.22-95.44%
1 Year254.16309.600.4233.402,284,480-253.58-99.77%
3 Years4,800.005,600.000.421,003.101,716,881-4,799.42-99.99%
5 Years4,800.005,600.000.421,003.101,716,881-4,799.42-99.99%

TransCode Therapeutics Description

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Your Recent History

Delayed Upgrade Clock